Geron Corporation
$ 1.29
-3.73%
31 Jul - close price
- Market Cap 827,562,000 USD
- Current Price $ 1.29
- High / Low $ 1.37 / 1.22
- Stock P/E N/A
- Book Value 0.36
- EPS -0.11
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE -0.27 %
- 52 Week High 2.01
- 52 Week Low 1.04
About
Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The company is headquartered in Foster City, California.
Analyst Target Price
$4.25
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-06 | 2026-02-25 | 2025-11-05 | 2025-08-06 | 2025-05-07 | 2025-02-26 | 2024-11-07 | 2024-08-08 | 2024-05-02 | 2024-02-28 | 2023-11-02 | 2023-08-03 |
| Reported EPS | -0.0049 | -0.0212 | -0.03 | -0.02 | -0.03 | -0.0356 | -0.04 | -0.1 | -0.09 | -0.09 | -0.08 | -0.09 |
| Estimated EPS | -0.02 | -0.028 | -0.03 | -0.03 | -0.04 | -0.0464 | -0.08 | -0.1 | -0.09 | -0.1 | -0.1 | -0.08 |
| Surprise | 0.0151 | 0.0068 | 0 | 0.01 | 0.01 | 0.0108 | 0.04 | 0 | 0 | 0.01 | 0.02 | -0.01 |
| Surprise Percentage | 75.5% | 24.2857% | 0% | 33.3333% | 25% | 23.2759% | 50% | 0% | 0% | 10% | 20% | -12.5% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.01 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GERN
2026-07-31 03:09:43
Geron Corporation (GERN) is scheduled to release its financial results on August 5, 2026, before the market opens. Analysts forecast an EPS of -$0.04 and revenue of $4 million for the quarter. Investors will be keenly watching these results to gauge the company's financial health and future prospects.
2026-07-30 08:41:02
Geron Corp (GERN) currently holds a valuation score of 7.81, placing it 191st out of 384 companies in the Biotechnology & Medical Research industry. The article highlights its P/E ratio of -13.88, which is a significant drop from its recent high, while noting that relevant P/B, P/S, and P/CF data are not yet disclosed by the company. The analysis provides key financial figures and market capitalization for GERN.
2026-07-29 23:40:20
This article provides an overview of market sentiment for Geron (GERN), highlighting analyst consensus, short interest, options flow, and recent insider activity. Key signals show a "Buy" analyst consensus, 12.5% rising short interest, and a bullish options flow with a 0.01 P/C ratio. The article also lists recent analyst ratings, price target changes, and related news, such as whale activity and insider stock acquisitions.
2026-07-29 09:10:01
Geron Corp (GERN) has a current financial score of 8.58, ranking 41 out of 385 in the Biotechnology & Medical Research industry, indicating a weak financial status but high operating efficiency. The company's latest quarterly revenue saw a 30.89% year-over-year increase, reaching $51.84M, while its net profit increased by 81.64% year-over-year. Key detailed financial data for aspects like cash and cash equivalents, total assets, total liabilities, and free cash flow have not been disclosed yet.
2026-07-29 01:42:00
This article from TradingKey attempts to provide a revenue breakdown for Geron Corp (GERN) by business segments and regional contributions. However, the site states that relevant financial data for these categories have not yet been disclosed by the company. Consequently, no specific revenue figures or breakdowns are presented.
2026-07-28 23:10:01
This article provides a comprehensive stock analysis of Geron Corp (GERN) by TradingKey, highlighting its stable fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. Despite positive analyst ratings and recent market outperformance, technical indicators suggest the stock is trading sideways. The analysis details key insights such as high institutional ownership, accelerated revenue growth, and specific strengths and risks related to its biopharmaceutical pipeline.
